- QMRO Home
- Barts Cancer Institute
- Centre for Haemato-Oncology
- Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
Browse
Administrators only